[Fundamental and clinical studies on cefminox].
Cefminox (CMNX, MT-141) was tried in children with various infection and the following results were obtained. Serum levels and urinary recovery of CMNX were studied in 2 patients aged with 9 and 11 years. After intravenous injection of 20 mg/kg, the mean serum concentrations at 15, 30 minutes, 1, 2, 4, and 6 hours after the administration were 178.7, 122.2, 73.9, 41.0, 14.0 and 5.3 micrograms/ml, respectively. The half-life in serum was 1.36 hours. The average urinary recovery rate of CMNX was 86.5% at 6 hours after the administration. The therapeutic efficacy was excellent in 18, good in 1 and poor in 1 patient, the efficacy rate being 95%. As for the side effects, slight elevation of S-GOT and drug fever were observed in 2 cases.
D000900:Anti-Bacterial Agents / Q000378:metabolism / Q000627:therapeutic use*; D001424:Bacterial Infections / Q000188:drug therapy*; D002513:Cephamycins / Q000378:metabolism / Q000627:therapeutic use*; D002648:Child; D002675:Child, Preschool; D005260:Female; D006193:Haemophilus influenzae / Q000187:drug effects; D006801:Humans; D007223:Infant; D007231:Infant, Newborn; D008297:Male; D008581:Meningitis / Q000378:metabolism; D008826:Microbial Sensitivity Tests; D011014:Pneumonia / Q000188:drug therapy
D000900:Anti-Bacterial Agents; D002513:Cephamycins; C046079:cefminox